Vis enkel innførsel

dc.contributor.authorWu, Che-Yuan
dc.contributor.authorXiong, Lisa Y.
dc.contributor.authorOuk, Michael
dc.contributor.authorRabin, Jennifer S.
dc.contributor.authorHerrmann, Nathan
dc.contributor.authorLanctôt, Krista L.
dc.contributor.authorKapral, Moira K.
dc.contributor.authorLaw, Marcus
dc.contributor.authorCogo Moreira, Hugo
dc.contributor.authorEdwards, Jodi D.
dc.contributor.authorSwardfager, Walter
dc.date.accessioned2023-04-05T09:28:19Z
dc.date.available2023-04-05T09:28:19Z
dc.date.created2023-01-05T14:32:56Z
dc.date.issued2022
dc.identifier.citationAlzheimer's and Dementia: Translational Research and Clinical Interventions. 2022, 8 (1), Artikkel e12243.en_US
dc.identifier.issn2352-8737
dc.identifier.urihttps://hdl.handle.net/11250/3062203
dc.description.abstractIntroduction Studies suggest associations between proton pump inhibitors (PPIs) and dementia risk; however, many neither considered histamine-2 receptor antagonists (H2RAs) nor baseline cognitive status. Methods Participants (National Alzheimer's Coordinating Center Database; 2005–2021) using a PPI or H2RA were compared. Covariate-adjusted Cox regression was used to estimate hazard ratios (HR) for progression from normal cognition to mild cognitive impairment (MCI), and from MCI to dementia over 5 years. In a propensity-score–matched subsample of mild–moderate Alzheimer's disease (AD), mixed-effects negative binomial regression was used to estimate decline in delayed recall memory. Results Compared to PPI, H2RA use was associated with earlier progression from MCI to dementia (HR = 1.40 [1.09–1.81]; n = 1701), and with faster memory decline in AD over time (rate ratio = 0.76 [0.64–0.92]; n = 628), but not with progression from normal cognition to MCI (HR = 0.94 [0.71–1.24]; n = 2784). Discussion Compared to PPIs, H2RAs were associated with cognitive decline, specifically among people with pre-existing cognitive impairment.en_US
dc.language.isoengen_US
dc.publisherWileyen_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/deed.no*
dc.titleGastric acid suppressants and cognitive decline in people with or without cognitive impairmenten_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.subject.nsiVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Psykiatri, barnepsykiatri: 757en_US
dc.subject.nsiVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Nevrologi: 752en_US
dc.source.volume8en_US
dc.source.journalAlzheimer's and Dementia: Translational Research and Clinical Interventionsen_US
dc.source.issue1en_US
dc.identifier.doi10.1002/trc2.12243
dc.identifier.cristin2101418
dc.source.articlenumbere12243en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal